Cargando…
MEDB-69. Clinical and molecular meta-analysis of three major medulloblastoma clinical trials (ACNS0331, SJMB03, ACNS0332) uncovers novel strategies to improve risk-stratified therapy
BACKGROUND: Given the vast molecular heterogeneity present within medulloblastoma (MB) and considerable differences in therapy, we performed a meta-analysis of three large, recently published, prospective clinical trials (ACNS0331, SJMB03, ACNS0332) comprising 898 children with newly-diagnosed MB to...
Autores principales: | Smith, Kyle S, Billups, Catherine A, Dhanda, Sandeep K, Bihannic, Laure, Vasilyeva, Aksana, Li, Yimei, Michalski, Jeff M, Olsen, James M, Leary, Sarah, Fouladi, Maryam, Gajjar, Amar, Onar, Arzu, Northcott, Paul A, Robinson, Giles W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165139/ http://dx.doi.org/10.1093/neuonc/noac079.443 |
Ejemplares similares
-
MBCL-15. IMPACT OF MOLECULAR SUBGROUPS ON OUTCOMES FOLLOWING RADIATION TREATMENT RANDOMIZATIONS FOR AVERAGE RISK MEDULLOBLASTOMA: A PLANNED ANALYSIS OF CHILDREN’S ONCOLOGY GROUP (COG) ACNS0331
por: Michalski, Jeff, et al.
Publicado: (2020) -
MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma
por: Smith, Kyle, et al.
Publicado: (2022) -
MEDB-74. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies
por: Northcott, Paul, et al.
Publicado: (2022) -
MEDB-82. Exploring cell-cell communication networks in medulloblastoma using single-cell genomics
por: Gabler, Lisa, et al.
Publicado: (2022) -
MBCL-16. EFFICACY OF CARBOPLATIN GIVEN CONCOMITANTLY WITH RADIATION AND ISOTRETINOIN AS A PRO-APOPTOTIC AGENT IN MAINTENANCE THERAPY IN HIGH-RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP
por: Leary, Sarah, et al.
Publicado: (2020)